human PTPN11 shRNA silencing AAV

BPTP3; CFC; JMML; METCDS; NS1; protein-tyrosine phosphatase 1D; protein-tyrosine phosphatase 2C; PTP-1D; PTP2C; PTP-2C; SHP2; SHP-2; SH-PTP2; SH-PTP3; tyrosine-protein phosphatase non-receptor type 11

PTPN11/Shp2 is a src-homology 2-containing protein-tyrosine phosphatase (PTP). PTPN11/Shp2 is a non-receptor phosphatase that mediates a variety of cytokine, growth factor, and hormone signals. Signal transduction by PTPN11/Shp2 is achieved via the activation of the Ras/mitogen-activated protein kinase pathway. Heterogenous gain of function mutations in PTPN11/Shp2 are associated with juvenile myelomonocytic leukemia (JMML) and Noonan syndrome, a disorder characterized by short stature, facial dysmorphology, and congenital heart defects.

PTPN11 is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. This PTP contains two tandem Src homology-2 domains, which function as phospho-tyrosine binding domains and mediate the interaction of this PTP with its substrates. This PTP is widely expressed in most tissues and plays a regulatory role in various cell signaling events that are important for a diversity of cell functions, such as mitogenic activation, metabolic control, transcription regulation, and cell migration. Mutations in this gene are a cause of Noonan syndrome as well as acute myeloid leukemia. Two transcript variants encoding different isoforms have been found for this gene.

5781

protein tyrosine phosphatase, non-receptor type 11

protein tyrosine phosphatase, non-receptor type 11

PTPN11

HGNC:9644

9606.0

1383

1383 bp

Tyrosine-protein phosphatase non-receptor type 11

NM_002834

NM_080601, NM_002834, NM_001330437, BC025181, BC008692,

Angiogenesis,Axon Guidance,B-cell Receptor Signaling,BDNF Signaling,Cancer,Cardiac Development,Cardiology,Cardiovascular,Cytokine Signaling,DNA Damage/Repair,EGFR Signaling,EGFR Signaling in Cancer,EPO Signaling,Fc Receptor Signaling,FGF Signaling,HGF Signaling,Host-Virus Interactions,IFN Signaling,IGF-1 Signaling,Immunology,Innate Immunity,Insulin Signaling,Interleukin Signaling,JAK-STAT Signaling,Kidney Cancer,Kinase/Phosphatase,Leptin Signaling,Leukemia,Metabolism/Metabolic Process,Mitochondrion,Neurobiology,NGF Signaling,PDGF Signaling,Phosphatase,PI3K/Akt Signaling,PI3K-AKT Signaling in Cancer,Prolactin Signaling,Prostate Cancer,SCF-KIT Signaling,Signal Transduction,T-cell Receptor Signaling,TNF Signaling,Toll-like Receptor Signaling,TSLP Signaling,Tumor Suppressors/Oncoproteins,VEGF Signaling

cancer,cardiovascular,cell_biology,developmental_biology,genetics,immunology,infectious_disease,metabolism,neurobiology,signal_transduction,stem_cell_biology,transcription_translation

human

PTPN11/Shp2 is a src-homology 2-containing protein-tyrosine phosphatase (PTP). PTPN11/Shp2 is a non-receptor phosphatase that mediates a variety of cytokine, growth factor, and hormone signals. Signal transduction by PTPN11/Shp2 is achieved via the activation of the Ras/mitogen-activated protein kinase pathway. Heterogenous gain of function mutations in PTPN11/Shp2 are associated with juvenile myelomonocytic leukemia (JMML) and Noonan syndrome, a disorder characterized by short stature, facial dysmorphology, and congenital heart defects.

Hs.506852

Q06124